Knowledge about buprenorphine and methadone among those receiving treatment for opioid dependence

Drugs: Education, Prevention and Policy

Volumn 15, Issue 4, 2008, Pages 395-409

  Winstock, Adam R ^a   Lea, Toby ^a   Madden, Annie ^b   Bath, Nicky ^b  

^a Drug Health Services   (Australia)

^b Australian Injecting and Illicit Drug Users' League (AIVL)   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 52949093107     PISSN: 09687637     EISSN: 14653370     Source Type: Journal    
DOI: 10.1080/09687630701425865     Document Type: Article

References (45)

1. Amass, L., Bickel, W. K., Crean, J. P., Blake, J., & Higgins, S. T. (1998). Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology, 136, 217-225.
2. Amass, L., Bickel, W. K., Higgins, S. T., & Badger, G. J. (1994). Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sciences, 54, 1215-1228.
3. Andrews, S., Sorensen, J. L., Guydish, J., Delucchi, K., & Greenberg, B. (2005). Knowledge and attitudes about methadone maintenance among staff working in a therapeutic community. Journal of Maintenance in the Addictions, 3, 47-59.
4. Aquilino, W. S. (1994). Interview mode effects in surveys of drug and alcohol use: A field experiment. Public Opinion Quarterly, 58, 210-240.
5. Bickel, W. K., Amass, L., Crean, J. P., & Badger, G. J. (1999). Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology, 146, 111-118.
6. Brown, C. S., Wright, R. G., & Christensen, D. B. (1987). Association between type of medication instruction and patients' knowledge, side effects, and compliance. Hospital and Community Psychiatry, 38, 55-60.
7. Cameron, C. (1996). Patient compliance: Recognition of factors involved and suggestions for promoting compliance with therapeutic regimens. Journal of Advanced Nursing, 24, 244-250.
8. Caplehorn, J. R. M., & Drummer, O. H. (2002). Fatal methadone toxicity: Signs and circumstances, and the role of benzodiazepines. Australian and New Zealand Journal of Public Health, 26, 358-363.
9. Caplehorn, J. R. M., Lumley, T. S., & Irwig, L. (1998). Staff attitudes and retention of patients in methadone maintenance programs. Drug and Alcohol Dependence, 52, 57-61.
10. Carter, J. C., Aimé, A. A., & Mills, J. S. (2001). Assessment of bulimia nervosa: A comparison of interview and self-report questionnaire methods. International Journal of Eating Disorders, 30, 187-192.
11. Chapman, K. R., Walker, L., Cluley, S., & Fabbri, L. (2000). Improving patient compliance with asthma therapy. Respiratory Medicine, 94, 2-9.
12. Cochrane, G. M., Home, R., & Chanez, P. (1999). Compliance in asthma. Respiratory Medicine, 93, 763-769.
13. Darke, S., Ross, J., & Hall, W. (1996). Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug and Alcohol Dependence, 43, 191-198.
14. Dietze, P., Jolley, D., Fry, C. L., Bammer, G., & Moore, D. (2006). When is a little knowledge dangerous? Circumstances of recent heroin overdose and links to knowledge of overdose risk factors. Drug and Alcohol Dependence, 84, 223-230.
15. Eisen, S. V. (1995). Assessment of subjective distress by patients' self-report versus structured interview. Psychological Reports, 76, 35-39.
16. Eissenberg, T., Johnson, R. E., Bigelow, G. E., Walsh, S. L., Liebson, I. A., Strain, E. C., et al. (1997). Controlled opioid withdrawal evaluation during 72h dose omission in buprenorphine-maintained patients. Drug and Alcohol Dependence, 45, 81-91.
17. Ernst, E., Bartu, A., Popescu, A., Ilett, K. F., Hansson, R., & Plumley, N. (2002). Mediadone-related deadis in Western Australia 1993-99. Australia and New Zealand Journal of Public Health, 26, 364-370.
18. Ezard, N., Lintzeris, N., Odgers, P., Koutroulis, G., Muhleisen, P., Stowe, A., et al. (1999). An evaluation of community methadone services in Victoria, Australia: Results of a client survey. Drug and Alcohol Review, 18, 417-423.
19. Fischer, B., Chin, A. T., Kuo, I., Kirst, M., & Vlahov, D. (2002). Canadian illicit opiate users' views on methadone and other opiate prescription treatment: An exploratory qualitative study. Substance Use and Misuse, 37, 495-522.
20. Gerlach, R., & Caplehorn, J. R. M. (1999). Attitudes and beliefs of doctors prescribing methadone to addicts in Westfalen-Lippe region of Germany. Drug and Alcohol Review, 18, 163-170.
21. Gmel, G. (2000). The effect of mode of data collection and of non-response on reported alcohol consumption: A split-sample study in Switzerland. Addiction, 95, 123-134.
22. Hill, J., Bird, H., & Johnson, S. (2001). Effect of patient education on adherence to drug treatment for rheumatoid arthritis: A randomised controlled trial. Annals of the Rheumatic Diseases, 60, 869-875.
23. Johnson, R. E., Strain, E. C., & Amass, L. (2003). Buprenorphine: How to use it right. Drug and Alcohol Dependence, 70, S59-77.
24. Jones, L., Edge, J., & Love, A. C. (2005). The effect of educational intervention on pharmacists' attitudes to substance misusers. Journal of Substance Use, 10, 285-292.
25. Kehoe, P., & Wodak, A. (2004). Patient satisfaction in a NSWpublic opioid pharmacotherapy clinic-Measurement and responses. Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales.
26. Kraus, L., & Augustin, R. (2001). Measuring alcohol consumption and alcohol-related problems: Comparison of responses from self-administered questionnaires and telephone interviews. Addiction, 96, 459-471.
27. Ling, W., & Smith, D. (2002). Buprenorphine: Blending practice and research. Journal of Substance Abuse Treatment, 23, 87-92.
28. Lintzeris, N., & Bath, N. (Eds.). (2000). Subutex® - A Guide to Treatment. Sydney, Australia: Reckitt Benckiser.
29. Lutfey, K. E., & Wishner, W. J. (1999). Beyond 'compliance' is 'adherence'. Improving the prospect of diabetes care. Diabetes Care, 22, 635-639.
30. Odeh, M., Oliven, A., & Bassan, H. (1992). Morphine and severe dryness of the lips. Postgraduate Medical Journal, 68, 303-304.
31. Parr, J., & Greenfield, T. (2000). Methadone maintenance treatment at Cairns Base Hospital: Client characteristics and client satisfaction. Australia: Alcohol, Tobacco & Other Drugs Service, Cairns Health Service District. Queensland Health.
32. Preston, A., & Doverty, M. (1999). The methadone handbook ed. (2nd ed.). Victoria, Australia: Australian Drug Foundation.
33. Rees, T. D. (1992). Oral effects of drug abuse. Critical Reviews in Oral Biology & Medicine, 3, 163-184.
34. Rosenblum, A., Magura, S., & Joseph, H. (1991). Ambivalence toward methadone treatment among intravenous drug users. Journal of Psychoactive Drugs, 23, 21-27.
35. Santolaria-Fernandez, F. J., Gomez-Sirvent, J. L., Gonzalez-Reimers, C. E., Batista-Lopez, J. N., Jorge-Hernandez, J. A., Rodriguez-Moreno, F., et al. (1995). Nutritional assessment of drug addicts. Drug and Alcohol Dependence, 38, 11-18.
36. Sheridan, J., Carson, T., & Aggleton, M. (2003). Providing dental health services to drug users: Testing a model for a community pharmacy advice and referral scheme. Pharmaceutical Journal, 271, 180-182.
37. Stancliff, S., Myers, E., Steiner, S., & Drucker, E. (2002). Beliefs about methadone in an inner-city methadone clinic. Journal of Urban Health, 79, 571-577.
38. Titsas, A., & Ferguson, M. M. (2002). Impact of opioid use on dentistry. Australian Dental Journal, 47, 94-98.
39. Van Ooijen, M., Ivens, U. I., Johansen, C., & Skov, T. (1997). Comparison of a self-administered questionnaire and a telephone interview of 146 Danish waste collectors. American Journal of Industrial Medicine, 31, 653-658.
40. Walsh, S. L., & Eissenberg, T. (2003). The clinical pharmacology of buprenorphine: Extrapolating from the laboratory to the clinic. Drug and Alcohol Dependence, 70, S13-27.
41. Walsh, S. L., Preston, K. L., Bigelow, G. E., & Stitzer, M. L. (1995). Acute administration of buprenorphine in humans: Partial agonist and blockade effects. Journal of Pharmacology and Experimental Therapeutics, 274, 361-372.
42. Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994). Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology and Therapeutics, 55, 569-580.
43. Ward, J., Mattick, R. P., & Hall, W. (1994). The effectiveness of methadone maintenance treatment: An overview. Drug and Alcohol Review, 13, 327-336.
44. Zador, D., & Sunjic, S. (2000). Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. Addiction, 95, 77-84.
45. Zador, D. A., & Sunjic, S. D. (2002). Methadone-related deaths and mortality rate during induction into methadone maintenance, New South Wales, 1996. Drug and Alcohol Review, 21, 131-136.